Back to All Events

ELRIG: 'PROTACs – An exciting therapeutic modality'

  • Alderley Park Conference Centre Congleton Rd England, SK10 United Kingdom (map)

Join the European Laboratory Research and Innovation Group for their next networking event.

Proteolysis targeting chimeras (PROTACs) offer a novel alternative to traditional small molecules. They inhibit proteins by binding to their functional regions and by recruiting E3 ligases to target the protein for degradation through the cells natural ubiquitin/proteasome pathway.

This event will focus on the recent developments in the field, provide an opportunity to learn about the types of protein complexes that are being considered as PROTAC targets and provide an introduction to those new to the field who are looking to start engaging with PROTACs within their own research. Informal presentations will be given by guest speakers followed by a networking session over food and drinks.

Confirmed Speakers & Presentation Titles

“PROTACs – Foundation and recent developments”
Thomas Hayhow (Medicinal Chemist, AstraZeneca)

“Understanding the role of class-I HDAC complexes: a precise method of targeting deacetylase activity in cells”
Shaun Cowley (Chair of Molecular Biology, University of Leicester)

“Small Molecule Designer Libraries for Mutant p53 Rescue”
John Spencer (Professor of Bio-organic Chemistry, University of Sussex)

An integrated chemistry and assay platform enabling client ubiquitin-system targeted drug discovery and towards supporting the development of PROTAC-based therapeutics
Jason Brown (Scientific Director, Ubiquigent)

“Bio-Techne as a partner for the discovery and development of PROTACs”
Robert Felix (Head of Product Management, Tocris)

“A toolkit for PROTAC characterisation and monitoring the pathway to degradation”
Craig Malcolm (Promega)